RNA buffers the phase separation behavior of prion-like RNA binding proteins by Maharana, Shovamayee et al.
 
 
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RNA buffers the phase separation behavior of prion-like RNA
binding proteins
Citation for published version:
Maharana, S, Wang, J, Papadopoulos, DK, Richter, D, Pozniakovsky, A, Poser, I, Bickle, M, Rizk, S,
Guillén-Boixet, J, Franzmann, TM, Jahnel, M, Marrone, L, Chang, Y-T, Sterneckert, J, Tomancak, P,
Hyman, AA & Alberti, S 2018, 'RNA buffers the phase separation behavior of prion-like RNA binding
proteins', Science, vol. 360, no. 6391, pp. 918-921. https://doi.org/10.1126/science.aar7366
Digital Object Identifier (DOI):
10.1126/science.aar7366
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Peer reviewed version
Published In:
Science
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 04. Jan. 2021
Title: RNA buffers the phase separation behavior of prion-like RNA-binding proteins 
 
Authors: Shovamayee Maharana1, Jie Wang1#, Dimitrios K. Papadopoulos1,2#, Doris Richter1, Andrey 
Pozniakovsky1, Ina Poser1, Marc Bickle1,6, Sandra Rizk1,5, Jordina Guillén-Boixet1, Titus M. 
Franzmann1, Marcus Jahnel1, Lara Marrone7, Young Tae Chang3,4, Jared Sterneckert7, Pavel 
Tomancak1, Anthony Hyman1*, Simon Alberti1* 
Affiliations: 
 
1Max Planck Institute for Cell and Molecular Biology, Pfotenhauerstraße 108, 01307 Dresden, Germany. 
2MRC Human Genetic Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Crewe Road, Edinburgh EH4 2XU, UK. 
3Center for Self-assembly and Complexity, Institute for Basic Science (IBS), Pohang 37673, Republic of Korea. 
4Department of Chemistry, Pohang University of Science and Technology (POSTECH), Pohang 37673, Republic of Korea. 
5B Cube –Center for Molecular Bioengineering, Technische Universitaet, Arnoldstraße 18, 01307 Dresden, Germany. 
6Biotechnology Centre, Technische Universität Dresden, Tatzeberg 47/49, 01307 Dresden, Germany. 
 
7Technische Universität Dresden- Centre for Molecular Regenerative Therapies Dresden, 01307 Dresden, Germany. 
 
# Equal contribution 
*Correspondence to:  alberti@mpi-cbg.de, hyman@mpi-cbg.de 
 
Abstract: Prion-like RNA binding proteins (RBPs) such as TDP43 and FUS are largely soluble in 
the nucleus but form solid pathological aggregates when mislocalized to the cytoplasm.What 
keeps these proteins soluble in the nucleus and promotes aggregation in the cytoplasm is still 
unknown. We report here that RNA critically regulates the phase behavior of prion-like RBPs. 
Low RNA/protein ratios promote phase separation into liquid droplets, whereas high ratios 
prevent droplet formation in vitro. Reduction of nuclear RNA levels or genetic ablation of 
RNA binding causes excessive phase separation and the formation of cytotoxic solid-like 
assemblies in cells. We propose that the nucleus is a buffered system in which high RNA 
concentrations keep RBPs soluble. Changes in RNA levels or RNA binding abilities of RBPs 
cause aberrant phase transitions. 
 
One Sentence Summary: RNA regulates the phase behavior and prevents pathological 
aggregation of RNA-binding proteins. 
 
 
Main text: 
 
The intracellular environment is organized into membraneless compartments that have 
been termed biomolecular condensates because they form by liquid-liquid phase separation 
(1, 2). These condensates often contain RNA binding proteins (RBPs) with distinctive 
domains, so-called prion-like domains which are structurally disordered and contain F1 polar 
amino acids (3) (Fig. 1A). Interactions between prion-like domains and additional interactions 
between RNAs and RNA binding domains drive the assembly of prion-like RBPs by phase 
separation (4, 5). However, several prion-like RBPs, such as FUS, TDP43, and hnRNPA1, 
can also undergo an aberrant transition from a liquidlike state into solid aggregates that has 
been linked to neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) (4–6). 
One important aspect of these diseases is that aggregate formation is strongly associated with 
the subcellular location of the proteins. Aggregates in patient neurons are usually found in the 
cytoplasm, whereas the nucleus is usually devoid of the aggregating proteins (7–10), although 
there are some noteworthy exceptions (11). Disease causing mutations frequently affect the 
nuclear partitioning of prion-like RBPs (12, 13), highlighting the importance of cytoplasmic 
localization. Protein mislocalization to the cytoplasm causes loss-of-function and gain-of-
function phenotypes that are thought to underlie disease (14–17). Importantly, genetic 
relocalization of FUS to the nucleus in yeast strongly decreases FUS toxicity (18). This 
suggests that the localization of FUS to the nuclear environment suppresses its pathological 
behavior, which raises two important questions: What prevents prion-like RBPs from forming 
solid-like aggregates in the nucleus? And why do these RBPs form aggregates in the 
cytoplasm? 
 
To answer these questions, we investigated the phase behavior of several prion-like RBPs 
(Fig. 1A). First, we determined the nuclear concentrations of these proteins. The values 
ranged from 0.2 µM for TAF15 to 42.3 µM for hnRNPA1 (Fig. 1, B to D, and supplementary 
methods). Next, we purified these proteins as green fluorescent protein (GFP) fusions and 
added them to a physiological buffer. At a concentration similar to the nuclear concentration 
(7.6 µM), FUS phase separated into droplets (Fig. 1, E and F). This behavior contrasted with 
that in living cells, where only 1% of the nuclear FUS protein was contained in condensates 
(Fig. 1F), which are paraspeckles (19). The remaining 99% of nuclear FUS protein was 
diffusely localized. Similar observations were made for TDP43, EWSR1, TAF15, and 
hnRNPA1 (Fig. 1G, lower panels). These results suggest that although the protein 
concentration is high enough for phase separation in the nucleus, an additional nuclear factor 
prevents phase separation. 
 
We hypothesized that nuclear RNA could regulate the phase behavior of prion-like RBPs. To 
test this idea, we performed an in vitro phase separation assay with FUS in the presence of 
total RNA (Fig. 2A). In agreement with previous work F2 (20–22), we found that small 
amounts of RNA promoted liquid droplet formation (Fig. 2B and fig. S1, A to D). RNA-
containing droplets contained a higher FUS concentration than RNA free droplets, and they 
appeared slightly more viscous (fig. S2, A to C). However, upon further increase in the 
RNA/protein concentration ratio, the droplets became smaller and finally dissolved (Fig. 2, A 
and B, and fig. S3). The addition of RNase A resulted in droplet reappearance (Fig. 2D and 
figs. S4A, panels on the right, and S5), indicating that droplet solubilization depends on intact 
RNA. Similar results were obtained for EWSR1, TAF15, hnRNPA1, and TDP43 (Fig. 2C). 
Thus, we conclude that high RNA/protein ratios prevent phase separation and that low ratios 
promote phase separation.  
 
We next tested whether different types of RNAs differ with respect to their abilities to 
dissolve FUS droplets. Individually, ribosomal RNA, tRNA, and a noncoding RNA that is 
known to bind to FUS (Neat1) were all able to solubilize FUS droplets, suggesting a general 
effect, but smaller RNAs were more potent than larger ones (fig. S4, A to D). Secondary 
structure was important for enriching FUS in droplets, consistent with results in previous 
work (20), but secondary structure (fig. S4, A to E) and binding affinity (fig. S6) affected 
droplet solubilization only slightly. We next asked whether the cellular RNA concentration is 
high enough to suppress phase separation of FUS. We estimated that the nuclear RNA 
concentration is ~10.6 times as high as that required for droplet dissolution in vitro (fig. S7 
and supplementary methods). However, ~1% of nuclear FUS formed condensates 
(paraspeckles) (Fig. 1E) by binding to the noncoding RNA Neat1 (19). To test whether Neat1 
could nucleate FUS droplets in the presence of a high background concentration of RNA, we 
added Neat1 RNA to a FUS sample that had been solubilized with tRNA. This led to a 
reappearance of FUS droplets (Fig. 2E and fig. S4F). We attribute this result to the ability of 
Neat1 to form large RNA assemblies (fig. S4C), which subsequently recruit FUS. This 
observation suggests that highly structured RNAs such as Neat1 act as scaffolds that promote 
the nucleation of condensates in the high–RNA concentration environment of the nucleus. A 
similar scenario may apply for stress granules in the cytoplasm, which contain large amounts 
of structured polyadenylated mRNA (fig. S8). 
 
To test experimentally whether the high nuclear RNA concentration keeps FUS soluble, we 
microinjected ribonuclease A (RNase A) into the nuclei of HeLa cells. Immediately after 
RNase A injection, FUS-GFP condensed into many liquidlike droplets (Fig. 3A, fig. S9, and 
movie S1), and this effect was not due to a general loss of nuclear integrity (figs. S10 and 
S11). As an alternative approach to decrease the RNA/protein ratio, we injected purified FUS-
GFP into the nucleus, which led to an immediate increase in the number and size of nuclear 
FUS assemblies (fig. S12). RNase A microinjection into the nucleus also triggered rapid 
phase separation of hnRNPA1, EWSR1, TDP43, and TAF15 (figs. S13 and S14). To 
investigate whether FUS forms complexes with RNA in living cells, we used fluorescence 
correlation spectroscopy (FCS). We identified two populations of FUS, one slow moving and 
one fast moving (details are in supplementary methods). We estimate that the amount of slow 
FUS in the nucleus is 10 times as high as that in the cytoplasm (Fig. 3, B to D; fig. S15, A to 
E; and supplementary methods). The fraction of slow FUS in the nucleus was decreased by 
the mutation of RNA binding domains in FUS (generating variants FUS-mutRRM/ZnF and 
FUS-mutRGG2) and was further decreased by the removal of all RNA binding domains 
(generating variant FUSPLD) (Fig. 3, E and F, and figs. S15, F to I; S16; and S17). These 
results indicate that a large fraction of nuclear FUS is complexed with RNA. To further 
investigate the solubilizing role of RNA, we performed genetic experiments with transfected 
FUS-GFP–encoding plasmids. We observed that the number of nuclear FUS assemblies was 
directly proportional to the nuclear FUS concentration (Fig. 3G). We further found that FUS 
variants with a weaker capacity to bind RNA generally formed a higher number of assemblies 
(Fig. 3, H to J, and figs. S16 and S17). Thus, reduced RNA binding directly affects the 
solubility and decreases the saturation concentration at which FUS phase-separates.  
 
We showed previously that FUS in vitro initially forms liquid-like assemblies, but these 
mature into more solid-like gels and fibrils over time (5). These solid-like states are 
reminiscent of pathological aggregates in ALS (8, 9). Thus, we next tested whether the 
addition of RNA prevents the formation of fibrils in vitro. The addition of RNA kept the 
droplets in a soluble state, and fibers were not seen (Fig. 4A). We next investigated whether 
RNA also changes the material properties of FUS assemblies in vivo. We set up an in vivo 
aging assay in which we microinjected RNase A into HeLa cells and then monitored the 
dynamics of the liquid-like drops. After about 30 min, the FUS drops no longer fused (Fig. 4, 
B and C, and movie S2) but stuck together in large clusters, similar to phenotypes seen 
previously in vitro (Fig. 4D and movie S3). A change in the material properties was also 
evident from photobleaching experiments (Fig. 4, E and F, and fig. S18, A and B). Similar 
results were obtained for TDP43, but the transition was much faster (fig. S19 and movie S4). 
We next used a genetic approach to test how RNA binding affects the dynamics of FUS in 
vivo. Complete abrogation of RNA binding resulted in a marked decrease of mobile FUS 
(Fig. 4, G, H, and J, and fig. S18C) and the formation of sticky droplet clusters (Fig. 4K). 
Lastly, we used a chemical approach with the dye F22 to reduce RNA binding (23). In F22-
treated cells, the fraction of RNA-bound FUS was strongly diminished (fig. S20 and 
supplementary methods), and this caused a strong reduction in the mobile fraction of FUS 
(Fig. 4, I and J, and fig. S18, E and F). Together, these findings show that RNA keeps 
condensates formed by prion-like RBPs in a dynamic state and prevents the formation of solid 
assemblies that can cause disease.  
 
To investigate how reduced RNA binding affects cell viability, we transiently transfected 
HeLa cells with wild-type and mutant FUS and monitored cell survival. Expressing a nuclear 
variant with reduced RNA binding (FUS-mutRRM/ZnF) affected the rate of cell death only 
slightly (Fig. 4, L and M, and fig. S16), presumably because the high nuclear RNA 
concentration compensated for the genetic defect. However, targeting the very same variant to 
the cytoplasm by removing the nuclear localization sequence (NLS; generating FUS-
mutRRM/ZnF∆NLS) led to a strong increase in cell death, which was likely caused by the 
high propensity of this variant to form solid aggregates (figs. S21 to S23). Importantly, this 
increase was not observed for a cytosolic variant of FUS with normal RNA binding 
(FUS∆NLS). Thus, we conclude that excessive phase separation in the cytoplasm owing to 
low RNA levels induces a pathological state that leads to cell death. 
 
One of the key questions in protein misfolding diseases caused by prion-like RBPs is why 
these proteins aggregate in the cytoplasm rather than the nucleus. In this study, we have 
shown that this pattern is due in part to different RNA concentrations in the cytoplasm and the 
nucleus. More specifically, the higher RNA concentration in the nucleus suppresses phase 
separation of prion-like RBPs, and the lower concentration in the cytoplasm stimulates phase 
separation. Therefore, by keeping the proteins in the nucleus, the cell ensures that they are in 
a soluble and nontoxic state, shuttling them out of the nucleus only upon stress. After the 
removal of stress, the proteins shuttle back into the nucleus, where they are again kept in a 
soluble and well-mixed state. The consequence is that any insult that prolongs the stress will 
tend to increase the propensity for aggregation because it prolongs the time that these proteins 
spend in the cytoplasm (fig. S24). 
 
Our data also have important implications for the control of phase separation in cells. We find 
that paraspeckles are likely induced by locally concentrating Neat1 RNA, which has a strong 
affinity for FUS. Similar phenomena have been seen for nucleoli, which depend on local 
production of ribosomal RNA (24). Therefore, at least in the nucleus, local production of 
RNAs with high affinity for specific RBPs may provide the specificity to induce phase 
separation in a system buffered by nonspecifically interacting RNA. Thus, the phase behavior 
of FUS in the nucleus is likely controlled by many different types of specific and nonspecific 
RNAs. This situation does not apply to the cytoplasm. There, the RNA concentration is only 
slightly higher than the concentration required to suppress phase separation in vitro and there 
is no buffering of phase separation by RNA. This environment results in a much higher 
propensity of FUS to phase-separate. However, it also increases the tendency of FUS to form 
cytotoxic solid-like aggregates. Large amounts of RNA have been shown to suppress the 
toxicity of prion-like RBPs (25–28). Moreover, there are many cases of familial ALS in 
which mutated prion-like RBPs mislocalize to the cytoplasm and form cytotoxic aggregates. 
For example, mutations in FUS have been shown to increase its cytoplasmic concentration, 
thus causing the formation of aberrant solid-like aggregates (8, 9, 29–31). We predict that 
local changes in RNA levels or RNA binding abilities of proteins are frequent causes of age-
related protein misfolding diseases. 
 
  
 
Fig. 1. Prion-like RBPs phase-separate at their physiological concentrations. 
(A) Domain structure. PLD, prion-like domain; RRM, RNA recognition motif; RGG, 
arginine- and glycine-rich region; ZF, zinc finger; NLS, nuclear localization sequence. (B) 
Representative images of immunostained HeLa cells. Dashed lines indicate the nuclear 
boundary. Scale bar, 5 µm. (C) Quantification of the nuclear enrichment of RBPs. Error bars 
represent SD. (D) Calculated cellular and nuclear (Nuc) concentrations of RBPs in HeLa 
cells. (E) Left, live HeLa cell nucleus expressing GFP-tagged FUS from a bacterial artificial 
chromosome (BAC). Arrows point to paraspeckles. Right, FUS-GFP phase-separated in vitro 
at 7.5 µM. Scale bars, 2 µm. (F) Quantification of the fractions of FUS present in condensed 
and soluble states in vivo and in vitro. Error bars represent SD. (G) Top, HeLa cell nuclei 
expressing GFP-tagged RBPs from BACs. White arrows indicate condensates. Bottom, 
purified RBPs phase-separate at their respective nuclear concentrations. Scale bars, 2 µm. 
  
 
 
Fig. 2. RNA regulates the phase behavior of prion-like RBPs. (A) Representative images 
of purified FUS-GFP (5 µM) in vitro in the presence of total RNA. (B) Quantification of the 
fraction of condensed FUS-GFP. Cin, fraction of total protein in the droplets; Cout, fraction 
of total protein in the soluble phase outside the droplets. The value of FUS enrichment in the 
droplet phase in the absence of RNA was normalized to 1. Error bars represent SD. (C) In 
vitro phase separation assay with EWSR1, TAF15, hnRNPA1, or TDP43 in the presence of 
total RNA. (D) Addition of RNase A to a sample of FUS-GFP (5 µM) solubilized with 300 
ng/ml of total RNA. (E) Left, FUS-GFP (5 µM) solubilized with 800 ng/ml tRNA in vitro. 
Right, FUS phase separation triggered by the addition of 100 ng/µl Neat1 RNA in the 
presence of tRNA (800 ng/µl). Scale bars in (A), (C), (D), and (E), 2 µm. 
 
 
 
 
  
Fig. 3. RNA keeps prion-like RBPs in a soluble state in the nucleus. 
(A) Montage of a HeLa cell expressing FUS-GFP after microinjection with RNase A. Scale 
bar, 2 µm. (B) HeLa cells expressing FUS-GFP. White lines indicate cell outlines, orange 
lines indicate nuclear outlines, and boxes indicate regions of FCS measurements. Scale bar, 5 
µm. (C) Autocorrelation curves obtained from FCS of FUS-GFP.  is the autocorrelation time 
and Gn () is the autocorrelation function, which is normalized to the amplitude of 1 at  = 10 
ms. (D) Quantification of the amount of slow FUS (methods are described in supplementary 
materials). Error bars represent SD. **P < 0.01. (E) Autocorrelation curves obtained from 
FCS of FUS-GFP variants in the nucleus. wt, wild type; mutRGG, mutations in the first RGG; 
mutRRM/ZnF, mutations in the RRM and zinc finger (ZnF); PLD, lacks all the RNA binding 
domains. (F) Quantification of slow FUS in the nucleus, obtained from two-component fits of 
the curves in (E) (methods are described in supplementary materials). Error bars represent 
SD. tD2, decay time for slow FUS. (G) HeLa cells showing variable FUS-GFP expression. 
Scale bar, 5 µm. (H) HeLa cells expressing different FUS-GFP variants with mutations in 
RNA binding domains (fig. S16). Scale bar, 5 µm. (I)Number of nuclear FUS-GFP 
assemblies per cell (n > 30) as a function of mean protein intensity (AI). Shading represents 
the confidence interval of the fitted linear regression model, which is plotted as a solid line. 
(J) Number of cells with more than 100 nuclear assemblies. n > 100 cells. Error bars represent 
SD. In (F) and (J), *P < 0.05 and ***P < 0.01 in comparison with the wild type. 
 
 
  
Fig. 4. RNA regulates aberrant liquid-to-solid phase transitions of prion-like RBPs.  
(A) In vitro phase-separated Gly156→Glu (G156E) variant FUS–GFP in the absence or 
presence of total RNA after 24 hours. Scale bar, 2 µm. (B) FUS-GFP–expressing HeLa cell 
nucleus after RNase A microinjection. Scale bar, 1 µm. (C) Montage of FUS-GFP droplets 
formed after RNase A microinjection. The droplets fuse in the first 5 min (blue box) but 
dissociate after 30 min, resulting in “sticky droplets” (red box). (D) Montage of FUS-GFP 
droplets formed in vitro (7 µM). The fusion of freshly formed droplets is compared with 3-
hour-old droplets. Scale bar, 5 µm. (E) Fluorescence recovery after photobleaching (FRAP) of 
nuclear FUS-GFP assemblies less than 5 min (blue box) or more than 30 min (red box) after 
RNase A microinjection. (F) FRAP of nuclear FUS-GFP assemblies in HeLa cells after RNA 
degradation as shown in (B) and (E) (n > 10 cells). (G to I) FRAP of nuclear assemblies in 
HeLa cells expressing full-length FUS [(G) and (I)] or FUS-PLD (H). The cell in (I) was also 
treated with F22. Scale bars, 1 mm. (J) Mobile fraction of photobleached assemblies in (G) to 
(I) (n > 15 cells). Error bars represent SD. (K) Three-dimensional (3D) rendering of FUS-
PLD nuclear assemblies.The insets show aberrant “sticky droplets.” Scale bar, 1 mm. (L) 
Time series to track the lifetime of FUS-GFP HeLa cells. H2B-mCherry was used to detect 
cell death. Scale bar, 5 mm. (M) Quantification of the fraction of cells undergoing cell death. 
Error bars represent SD. *P < 0.05, **P < 0.01, and ***P < 0.001 in comparison with the wild 
type.  
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